Immunomedics, Inc. (NASDAQ:IMMU) Files An 8-K Other Events
Item8.01. Other events
On March 2, 2017, Immunomedics, Inc. issued a press release
titled Immunomedics Outlines Revised Settlement Offer Rejected by
venBio; Announces Actions That Are in the Best Interests of All
Stockholders. The full text of the press release is attached to
this current report on Form8-K as Exhibit99.1 and is incorporated
by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description of Exhibit |
|
| 99.1 |
Press Release of Immunomedics, Inc., dated March 2, 2017, titled Immunomedics Outlines Revised Settlement Offer Rejected by venBio; Announces Actions That Are in the Best Interests of All Stockholders |
About Immunomedics, Inc. (NASDAQ:IMMU)
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials. Immunomedics, Inc. (NASDAQ:IMMU) Recent Trading Information
Immunomedics, Inc. (NASDAQ:IMMU) closed its last trading session up +0.27 at 5.43 with 2,720,693 shares trading hands.
